Alliança Saúde e Participações Valuation
Is AALR3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AALR3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AALR3 (R$13.95) is trading above our estimate of fair value (R$1.97)
Significantly Below Fair Value: AALR3 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AALR3?
Key metric: As AALR3 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is AALR3's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | R$1.19b |
| Market Cap | R$1.68b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | 32.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AALR3's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.5x | ||
DASA3 Diagnósticos da América | 0.1x | 6.6% | R$1.6b |
ONCO3 Oncoclínicas do Brasil Serviços Médicos | 0.4x | 11.7% | R$2.5b |
FLRY3 Fleury | 1x | 6.5% | R$7.5b |
MATD3 Hospital Mater Dei | 0.7x | 5.6% | R$1.5b |
AALR3 Alliança Saúde e Participações | 1.4x | n/a | R$1.7b |
Price-To-Sales vs Peers: AALR3 is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (0.5x).
Price to Sales Ratio vs Industry
How does AALR3's PS Ratio compare vs other companies in the South American Healthcare Industry?
| 5 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: AALR3 is expensive based on its Price-To-Sales Ratio (1.4x) compared to the South American Healthcare industry average (0.8x).
Price to Sales Ratio vs Fair Ratio
What is AALR3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate AALR3's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Centene
US$29.0b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
C1NC34
US$337.21
7D
-3.4%
1Y
-4.4%
CVS Health
US$66.9b
Provides health solutions in the United States.
CVSH34
US$32.34
7D
0.2%
1Y
-3.1%
Hapvida Participações e Investimentos
R$23.8b
Operates in the health sector in Brazil.
HAPV3
R$2.95
7D
-6.9%
1Y
-36.4%